Isofol Medical: Fully focused on AGENT - DNB
"Q4’s operating loss was higher than expected, mainly due to continued higher R&D spending as well as costs related to the change of CEO. The 005-study has been concluded and the company’s full attention should now be on bringing arfolitixorin to market. We estimate continued high R&D spending going forward as more sites are expected to be opened. We have tweaked our estimated fair value to SEK14–42 (SEK18–49)."
Link to commissioned research below.
Link to commissioned research below.
Commissioned research feed